Beyond Air

Beyond Air emphasized at the Cantor conference that the LungFit platform is already winning hospitals, but future growth depends largely on FDA approval of Generation 2. Generation 2 would enable use during patient transport and expand the addressable US market potential to around $400 million and global potential to about $1 billion. The company confirms revenue forecasts of $8 million for 2026 and $16–18 million for 2027, with the revenue doubling contingent on Generation 2 approval; approval is still expected by the end of 2026. Beyond Air reports a customer retention rate well above 90%, has prepared manufacturing sites for FDA inspection, and recently secured $10 million in financing, with a potential additional $20 million through option exercise. » Plus sur de.investing.com

Beyond Air sells its approximately 58% stake in NeuroNOS to Univo and receives common shares equal to 19.99% of Univo, plus warrants for an additional 19.99% (exercise price $0.01; term five years). Certain IP and development assets of NeuroNOS will be transferred to NeuroNOS. Beyond Air is entitled to development milestones of up to $6.5 million and commercial milestones of up to $26.0 million. The transaction is subject to regulatory, exchange- and consent-related approvals and other customary closing conditions. » Plus sur de.investing.com

Beyond Air announced that a 1:20 reverse stock split brought its minimum bid price to at least $1.00; the stock recorded 17 trading days with closing prices of at least $1.00 from July 13 to August 4 and therefore remains listed on Nasdaq, but is subject to a one-year monitoring period. The company reported fiscal 2026 revenue rising to $7.7 million and a positive gross profit of $300,000, while net loss narrowed to $33.2 million ($4.01 per share). The stock last traded at $5.56, is down roughly 90% from a year earlier, and has a market capitalization of about $4.08 million; in pre-market trading it fell about 9.85%. » Plus sur de.investing.com